Voß Hans W, Michalsen Andreas, Brünjes Rainer
CRO Dr. Kottmann GmbH & Co. KG, Hamm, Germany.
Immanuel Krankenhaus Berlin-Wannsee, Germany.
Drug Res (Stuttg). 2018 Aug;68(8):444-449. doi: 10.1055/s-0043-124179. Epub 2018 Mar 20.
A randomised, placebo-controlled clinical trial in children suffering from acute dry cough was performed to assess the efficacy and tolerability of a complex homeopathic drug (Drosera, Coccus cacti, Cuprum Sulfuricum, Ipecacuanha=Monapax syrup, short: verum).
89 children received verum and 91 received placebo daily for 7 days (age groups 0.5-3, 4-7 and 8-12 years). The primary efficacy variable was the improvement of the Cough Assessment Score. Tolerability and compliance were also assessed. A confirmatory statistical analysis was performed for the primary efficacy variable and a descriptive analysis for the secondary parameters.
The Cough Assessment Score showed an improvement of 5.2±2.6 points for children treated with verum and 3.2±2.6 points in the placebo group (p<0.0001). The difference of the least square means of the improvements was 1.9±0.4. The effect size of Cohen´s d was d=0.77. In all secondary parameters the patients in the verum group showed higher rates of improvement and remission than those in the placebo group. In 15 patients (verum: n=6; placebo: n=9) 18 adverse drug reactions of mild or moderate intensity were observed.
Administering verum resulted in a statistically significantly greater improvement of the Cough Assessment Score than the placebo. The tolerability was good and not inferior to that of the placebo.
开展了一项针对患有急性干咳儿童的随机、安慰剂对照临床试验,以评估一种复方顺势疗法药物(毛毡苔、仙人掌球菌、硫酸铜、吐根=莫纳帕克糖浆,简称:试验药物)的疗效和耐受性。
89名儿童每日服用试验药物,91名儿童每日服用安慰剂,持续7天(年龄组为0.5 - 3岁、4 - 7岁和8 - 12岁)。主要疗效变量为咳嗽评估评分的改善情况。还评估了耐受性和依从性。对主要疗效变量进行了验证性统计分析,对次要参数进行了描述性分析。
服用试验药物的儿童咳嗽评估评分改善了5.2±2.6分,安慰剂组改善了3.2±2.6分(p<0.0001)。改善的最小二乘均值差异为1.9±0.4。科恩d效应量为d = 0.77。在所有次要参数方面,试验药物组患者的改善和缓解率均高于安慰剂组。在15名患者中(试验药物组:n = 6;安慰剂组:n = 9)观察到18例轻度或中度强度的药物不良反应。
与安慰剂相比,服用试验药物在统计学上使咳嗽评估评分有更显著的改善。耐受性良好,且不低于安慰剂。